Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Nick Abbott's Stock Ratings
Wells Fargo Analyst
Nick Abbott is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/04/2025
Overall Average Return
-36.1%
Smart Score
Overall Average Return Percentile
5th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10/04/2022 | ZYME | Buy Now | Zymeworks | $12.96 | -30.56% | Nick Abbott19% | $45 → $9 | Assumes | → Overweight | Get Alert |
| 10/04/2022 | TCRT | Buy Now | Alaunos Therapeutics | $2.41 | 24.48% | Nick Abbott19% | → $450 | Assumes | → Overweight | Get Alert |
| 10/04/2022 | ADAP | Buy Now | Adaptimmune Therapeutics | $0.28 | 444.27% | Nick Abbott19% | $7 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | CALA | Buy Now | Calithera Biosciences | $0.01 | 39900% | Nick Abbott19% | $60 → $40 | Maintains | Equal-Weight | Get Alert |
| 05/04/2022 | TCRT | Buy Now | Alaunos Therapeutics | $2.41 | 24.48% | Nick Abbott19% | → $450 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 01/06/2022 | CLLS | Buy Now | Cellectis | $1.65 | 869.76% | Nick Abbott19% | → $16 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/24/2021 | AFMD | Buy Now | Affimed | $0.98 | 1430.61% | Nick Abbott19% | $100 → $150 | Maintains | Overweight | Get Alert |
| 08/10/2016 | ZIOP | Buy Now | ZIOPHARM Oncology | — | — | Nick Abbott19% | — | Upgrade | Underperform → Market Perform | Get Alert |
| 12/04/2015 | ZIOP | Buy Now | ZIOPHARM Oncology | — | — | Nick Abbott19% | — | Initiates | → Underperform | Get Alert |
| 10/27/2014 | CALA | Buy Now | Calithera Biosciences | $0.01 | — | Nick Abbott19% | — | Initiates | → Outperform | Get Alert |
